Also from this source

You just read:

Xynomic Pharma Initiates Ph 1/2 Trial Combining Abexinostat with Ibrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) and Mantle Cell Lymphoma (r/r MCL)

News provided by

Xynomic Pharmaceuticals, Inc.

Dec 01, 2017, 21:30 EST